Icosavax raises $51M Series A led by Qiming to build computer-designed VLP vaccines, starting with an adult RSV shot

Icosavax, a University of Washington spinout, raised $51 million in a Series A led by Qiming Venture Partners USA to develop computer-designed virus-like particle vaccines, starting with an adult RSV vaccine and planning broader applications.

No comments yet.